These findings suggest that a combination of a HER2-inhibitor and a c-Met-inhibitor might exert a greater effect than a HER2-inhibitor alone in HER2-positive gastric cancer patients with lymph node metastasis. The gene discussed is ERBB2; the disease is metastatic malignant neoplasm in the lymph nodes.